| LIMN 0.1477 29.00% | BITO 8.72 -0.94% | AAL 15.6 -0.19% | NU 13.79 -0.65% | ATAI 7.15 33.40% | EOSER 0.0283 -3.08% | OPEN 4.57 -3.79% | NOK 10.375 -7.78% | TGHL 1.52 86.62% | IQST 1.22 38.45% | NVDA 207.4 -2.40% | ONDS 6.65 -5.67% | INTC 96.98 -5.84% | PATH 12.03 0.67% | NVD 4.75 4.40% | T 21.99 2.61% | SOXL 142.48 -13.94% | SOFI 17.32 -3.08% | PLUG 2.15 -2.71% | TQQQ 70.74 -4.97% | NFLX 74.35 0.91% | AAPL 333.26 1.76% | SOXS 52.02 13.14% | STAK 3.58 68.08% | ORCL 124.27 -6.20% | SPCX 131.11 -3.08% | SKHY 152.31 -13.69% | SQQQ 40.89 5.01% | ASTS 55.01 -17.04% | SPDN 8.65 0.52% | JOBY 7.34 -5.41% | MU 853.2 -5.65% | KAPA 0.3399 6.89% | LCID 6.46 8.57% | AMZN 249.89 -1.99% | PFE 25.14 1.29% | MARA 11.42 -7.08% | TE 5.94 -10.81% | TSLL 12.02 -1.64% | MUU 27.51 -12.02% | EOSE 3.96 -9.38% | GOOGL 354.46 -4.44% | SPY 750.72 -0.54% | RIVN 17.09 -3.99% | IREN 34.83 -9.01% | HL 14.52 -6.08% | RKT 14.9 2.03% | DFNS 0.0493 -28.86% | DNN 2.85 -7.77% | ATPC 4.2 66.67%

Market Declines: Key Stocks and ETFs See Significant Drops Today

Exchange-traded funds (ETFs) also saw sharp moves. The Defiance Daily Target 2X Short MU ETF (NASDAQ:MUZ) fell 33.28% to $9.08. As a new fund for traders betting against Micron Technology (NASDAQ:MU), this drop indicates Micron Technology's stock likely performed well. A short ETF is designed to gain value when the underlying asset falls.

Similarly, the Daily Target 2X Long MSTR ETF (NASDAQ:MSTX) declined 18.65% to $7.33. This leveraged fund aims to provide twice the daily return of MicroStrategy (NASDAQ:MSTR)'s stock. Its fall shows that MicroStrategy shares also experienced a significant price drop during the day's trading, with the ETF magnifying that loss.

In the healthcare sector, IceCure Medical Ltd (NASDAQ:ICCM) shares fell 24.52% to $7.02. The drop for the tumor treatment device maker came despite recent news that it had regained compliance with Nasdaq's minimum $1.00 bid price requirement, which is generally a positive milestone for a company.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) recorded a 23.91% drop to $8.02. This was linked to the company not securing additional insurance coverage for its Neffy allergy spray. Despite this setback, ARS Pharmaceuticals reaffirmed its goal to reach cash-flow breakeven, where cash intake matches expenses, by 2027.

In summary, the day's declines were driven by different factors. ETF values moved based on their underlying assets' performance. For companies like ARS Pharmaceuticals, specific business news, such as failing to secure new insurance coverage, was a direct cause for the stock's sharp fall.

Published on: June 25, 2026